What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

by Guilherme Rasia Bosi, Laura Maria Fogliatto, Tito Emilio Vanelli Costa, Kamila Castro Grokoski, Mariana Pinto Pereira, Nathan Bugs, Marco Kalil, Christina Fraga, Liane Esteves Daudt, Lucia Mariano da Rocha Silla
Published 2019-07-01